Semaglutide placebo

DRUG11 trials

Conditions

Alzheimer DiseaseDiabetes Mellitus, Type 2Glucose Intolerance After a Recent History of Gestational DiabetesGlycemic Control for Diabetes MellitusInsulin Sensitivity/ResistanceLipidomicsMetabolic SyndromeMetabolomics

Phase 2

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

CompletedNCT05016882

Novo Nordisk A/SNon-alcoholic Steatohepatitis

Start: 2021-08-31End: 2025-03-14Updated: 2025-11-19

COMMETS- Combination MCI Metabolic Syndrome

RecruitingNCT06072963

Rutgers, The State University of New JerseyAlzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome

Start: 2024-01-30End: 2028-12-01Target: 80Updated: 2026-07-27

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

RecruitingNCT07639021

Novo Nordisk A/SObesity

Start: 2026-06-09End: 2027-07-12Target: 230Updated: 2026-07-10

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

RecruitingNCT07668388

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2026-06-22End: 2027-11-15Target: 300Updated: 2026-08-10

Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study

Not yet recruitingCTIS2026-525465-42-00

Novo Nordisk A/SType 2 diabetes (T2D)

Target: 110Updated: 2026-09-01

Phase 3

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

RecruitingNCT05569772

Universitaire Ziekenhuizen KU LeuvenGlucose Intolerance After a Recent History of Gestational Diabetes

Start: 2023-09-14End: 2029-12-01Target: 252Updated: 2026-07-07

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

CompletedNCT05890976

Novo Nordisk A/SOverweight, Obesity

Start: 2023-05-30End: 2025-01-16Updated: 2026-01-22

A randomised double-blind placebo-controlled clinical study investigating the effects of semaglutide s.c. once-weekly versus placebo on central and peripheral inflammation in participants with Alzheimer’s disease.

CompletedCTIS2023-506825-13-00

Novo Nordisk A/SMild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

Start: 2023-07-25End: 2025-06-26Target: 13Updated: 2025-02-17

Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS)

Active, not recruitingCTIS2023-506827-26-00

Novo Nordisk A/SWhile it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

Start: 2019-05-02Target: 589Updated: 2025-12-16

Semaglutide Treatment in Type 1 Diabetes

Not yet recruitingNCT06909006

Nordsjaellands HospitalObesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM) +6

Start: 2025-10-31End: 2028-06-30Target: 122Updated: 2025-08-08

Phase 4

eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity)

RecruitingCTIS2023-506289-29-00

Vestfold Hospital TrustObesity

Start: 2025-02-28Target: 220Updated: 2025-01-24

Related Papers

Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.

2026-07-23

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.

2026-07-15

From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis

Clinical Liver Disease2023-01-132 citations